Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | The role of SLAMF7-positive, CD8-positive T-cells in therapeutic resistance in kidney cancer

David A. Braun, MD, PhD, Yale School of Medicine, New Haven, CT, explains how a transitional study used advanced genomic techniques, such as single cell approaches, to uncover the causes of resistance to anti-PD1 therapy. Single cell RNA sequencing analysis from various clinical trial samples showed that slightly exhausted T-cells that expressed markers such as SLAMF7, were strongly linked with therapeutic resistance. This finding needs to be corroborated in other studies and requires functional testing, to uncover if this is a biomarker, predictive factor, or a component that can be modulated. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.